Clinical trial NCT05502705: The Effect of Intravenous Lidocaine on Postoperative Cognitive Function in Elderly Patients
Official title: Effects of Intravenous Lidocaine on Serum BDNF, NGF, miRNA-206 and miRNA-98 in Elderly Patients Undergoing Abdominal Surgery Under General Anesthesia
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Organ Protection
Keywords: Postoperative cognitive dysfunction
Lidocaine
Brain-derived neurotrophic factor
Nerve growth factor
miRNA-206
miRNA-98
Lead sponsor: General Hospital of Ningxia Medical University
Sponsor class: OTHER
First posted: 2022-08-16
Enrollment: 50
Sex: ALL
Minimum age (years): 65
Maximum age (years): 80
Standard ages: OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The purpose of this study is to investigate the efficacy of intravenous lidocaine on BDNF, NGF, miRNA-206 and miRNA-98 in serum in elderly patients undergoing abdominal surgery under general anesthesia.

Detailed description: Postoperative cognitive dysfunction (POCD) is a major complication following surgeries and anesthesia, especially in elderly individuals. Lidocaine, an inexpensive, widely available, and relatively safe compound, is a local anesthetic that readily crosses the blood-brain barrier. Intravenous lidocaine can reduce the incidence of POCD. However, the mechanism is still unclear.

Brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF), which are regulated by miRNA-206 and miRNA-98 respectively, play a key role in learning, memory, and cognition. Previous studies have shown that the levels of BDNF and NGF can be improved by lidocaine.

The objective of this study is to investigate the efficacy of intravenous lidocaine on the incidence of early POCD, and the levels of BDNF, NGF, miRNA-206 and miRNA-98 in elderly patients undergoing abdominal surgery under general anesthesia.

Eligibility criteria: Inclusion Criteria:

* Patients were scheduled by following abdominal surgery under general anesthesia
* Aged 65 - 80 years
* ASA physical status Ⅱ-Ⅲ

Exclusion Criteria:

* Severe heart, pulmonary, hepatic and renal insufficiency
* History of neurological diseases (including Alzheimer's disease and stroke history)
* Psychological disorder, and drug or alcohol abuse
* History of anesthesia and surgery
* psychiatric illness
* Unwillingness to comply with the protocol or procedures
* Allergic to lidocaine
* Mini-Mental State Examination (MMSE) score\<23 before surgery

Primary outcomes:
measure: Changes from Baseline BDNF at 1, 3 days after surgery
timeFrame: at preoperation,1 and 3 days postoperation
measure: Changes from Baseline NGF at 1, 3 days after surgery
timeFrame: at preoperation,1 and 3 days postoperation
measure: Changes from Baseline miRNA-206 at 1, 3 days after surgery
timeFrame: at preoperation,1 and 3 days postoperation
measure: Changes from Baseline miRNA-98 at 1, 3 days after surgery
timeFrame: at preoperation,1 and 3 days postoperation
Secondary outcomes:
measure: Changes from Baseline mini-mental state examination (MMSE) at 1, 3 days after surgery
timeFrame: at preoperation,1 and 3 days postoperation
Other outcomes:
measure: Postoperative cognitive dysfunction (POCD)
timeFrame: at preoperation,1 and 3 days postoperation
Locations:
Study officials:
References: